CONTINUFLO SOLUTION SET/SECONDARY MEDICATION SET— 510(k) K961225

Substantially Equivalent

Baxter Healthcare Corp

FDA 510(k) clearance K961225 for CONTINUFLO SOLUTION SET/SECONDARY MEDICATION SET, Substantially Equivalent on 1996-06-21. Applicant: Baxter Healthcare Corp.

Clearance details

Applicant: Baxter Healthcare Corp
Product code: Code FPA
Advisory panel: General Hospital
Date received: 1996-03-29
Decision date: 1996-06-21
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Round Lake, IL, US

Download summary PDF View on FDA.gov ↗

Adverse events under product code FPA

product code FPA

Death: 95
Injury: 14,421
Malfunction: 125,815
Other: 30
Total: 140,361

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.